Satraplatin
| CAS No. | 129580-63-8 | Cat. No. | BCP14387 |
| Name | Satraplatin | ||
| Synonyms | BMS182751; BMS 182751; BMS-182751; JM 216; JM-216; JM216; BMY45594; POplat; | ||
| Formula | C10H22Cl2N2O4Pt | M. Wt | 500.28 |
| Description | Satraplatin is the first orally active platinum-based chemotherapeutic drug. Other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously. It is made available in the United States jointly by Spectrum Pharmaceuticals and GPC Biotech under the name SPERA (SatraPlatin Expanded Rapid Access). The drug has also been used in the treatment of lung and ovarian cancers. The proposed mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing. | ||
| Pathways | Cell Cycle/DNA Damage | ||
| Targets | DNA Alkylator/Crosslinker | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.